Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Arcturus Therapeutics Holdings Inc.'s filing signal turned negative.

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger RNA (mRNA) medicines company focused on developing therapeutics for rare liver and respiratory diseases. The company has developed proprietary STARR(R) self-amplifying mRNA (sa-mRNA) and LUNAR(R) lipid-mediated delivery platforms, which have been demonstrated to induce robust, longer-lasting immune responses at lower doses than conventional mRNA vaccines. Arcturus has an approved COVID-19 vaccine, KOSTAIVE(R), marketed in Japan and Europe through a partnership with CSL Seqirus. Its internal pipeline includes ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency, both of which are in Phase 2 clinical development. The company also has vaccine programs for influenza and other infectious diseases, including a partnership with CSL Seqirus.

Revenue is primarily driven by upfront payments, milestone payments, and royalties from collaboration agreements, notably with CSL Seqirus for vaccine development, and by grant revenue from government agencies like BARDA.